Clinical trials: Kidney Transplant
Stenosis, Restenosis
Clinical Study of the BARD® COVERA™ Arteriovenous (AV) Stent Graft
The objective of this study is to assess the safety and effectiveness of the COVERA™ Vascular Covered Stent for the treatment of stenotic lesions in the upper extremity venous outflow of the Arteriovenous (AV) access circuit.
- Trial name
- AVeNEW (NCT02649946)
- Testing
- Covera Vascular Covered Stent following PTA, Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
- Where
- 24 sites in United States, Australia and 6 more
- Volunteers
- 280 people
- Sponsor
- C. R. Bard
Transplant; Failure, Kidney, Hypertension
The Impact of Nebivolol Versus Metoprolol on Quality of Life
In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population.
- Trial name
- NCT01441570
- Testing
- Nebivolol, Metoprolol succinate
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Brigham and Women's Hospital
Acute Renal Failure
Low Dose Thymoglobin in Renal Transplant Patients
This is a planned single center prospective randomized study evaluating the safety and efficacy of low dose thymoglobulin as induction agent in renal transplant recipients.
- Trial name
- NCT01280617
- Testing
- Thymoglobulin, Thymoglobulin 0.75mg/kg dose
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Lahey Clinic
Chronic Kidney Disease
Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
IdeS is an immunoglobulin g (IgG) cleaving enzyme. It will given to patients with donor specific antibodies to reduce the antibody load and thus enable kidney transplantation.
- Trial name
- NCT02224820
- Testing
- IdeS
- Where
- Sweden
- Volunteers
- 8 people
- Sponsor
- Hansa Biopharma AB
Kidney Transplant Rejection
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
The purpose of this study was to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have had an…
- Trial name
- NCT03897205
- Testing
- Imlifidase, Plasma Exchange
- Where
- 14 sites in United States, Australia and 3 more
- Volunteers
- 30 people
- Sponsor
- Hansa Biopharma AB
Renal Transplantation, Aging
Pneumococcal Conjugate Vaccine in Aging Renal Transplant
The goal of the research proposed in the current application is to first define how much antibody aging renal transplant and dialysis recipients make after they are vaccinated with the pneumonia vaccine and how this compares to…
- Trial name
- NCT03802994
- Testing
- 23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample
- Where
- 2 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Anemia, Iron-Deficiency, Kidney Failure, Chronic
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents…
- Trial name
- NCT00224042
- Testing
- Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
- Where
- 24 sites in United States, Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Watson Pharmaceuticals
Acute Pain, Arthropathy of Knee
NSS-2-BRIDGE Study for Total Knee and Hip Arthroplasties, Bariatric, and Kidney Transplant Surgeries
The current opioid epidemic has led to a renewed interest in exploring non-pharmacological techniques to treat post-operative pain.
- Conditions
- Acute Pain, Arthropathy of Knee, Arthropathy of Hip, Pain, Postoperative
- Trial name
- NCT03834142
- Testing
- NSS-2 Bridge
- Where
- 3 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Jacques E. Chelly
Liver Transplantation
Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy
The study is designed to show that everolimus initiation together with reduction and thereafter discontinuation of calcineurin inhibitor (CNI) will improve significantly renal function in de novo liver transplant recipients as…
- Trial name
- NCT00378014
- Testing
- everolimus, basiliximab, CNI
- Where
- 16 sites in Austria, Germany and 2 more
- Volunteers
- 276 people
- Sponsor
- Novartis Pharmaceuticals
Clostridium Difficile Infection Recurrence
Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Recurrent C. Diff
Subjects with recurrent C. difficile infection will receive an oral dose of CP101 capsules one time in Treatment Group I or matching placebo one time in Treatment Group II.
- Trial name
- PRISM3 (NCT03110133)
- Testing
- Full Spectrum Microbiota
- Where
- 58 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Finch Research and Development LLC.
Graft vs Host Disease, Kidney Transplantation
Study Evaluating Sirolimus in Kidney Transplant Recipients
The purpose of this study is to compare the kidney function in patients who have received a transplanted kidney and were treated with the combination of sirolimus, daclizumab, mycophenolate and corticosteroids versus transplanted…
- Trial name
- NCT00195273
- Testing
- sirolimus, cyclosporine, mycophenolate mofetil
- Where
- 3 sites in Norway, Sweden
- Volunteers
- 61 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Renal Transplantation
Study Evaluating The Use Of Sirolimus In Recipients Of Kidney Allografts From Expanded Criteria Donors (ECD)
The purpose of this observational study is to examine the clinical outcomes of the use of sirolimus as base therapy in kidney allograft recipients from Expanded Criteria Donors (ECD) under conditions of routine clinical practice.
- Trial name
- NCT00697112
- Testing
- Sirolimus
- Where
- 8 sites in Argentina
- Volunteers
- 53 people
- Sponsor
- Pfizer
Congestive Heart Failure, Cardiac Transplantation
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
The purposes of this study in United Network for Organ Sharing (UNOS) Status 1B (or country equivalent) cardiac transplant candidates are to assess the safety and efficacy of Natrecor (nesiritide).
- Conditions
- Congestive Heart Failure, Cardiac Transplantation, Renal Insufficiency, Renal Failure
- Trial name
- NCT00338455
- Testing
- Natrecor (nesiritide)+Standard Care+dobutamine or milrinone
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Scios, Inc.
Kidney Transplantation, Primary Focal Segmental Glomerulosclerosis (FSGS)
Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients
The purpose of this study was to assess the efficacy of the bleselumab regimen (basiliximab induction, tacrolimus, steroids and bleselumab) compared with the Standard of Care (SOC) regimen (basiliximab induction, tacrolimus…
- Trial name
- NCT02921789
- Testing
- Bleselumab, Basiliximab, Mycophenolate Mofetil (MMF)
- Where
- 23 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Antiphospholipid Antibody Syndrome, End Stage Renal Disease
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome
Catastrophic Antiphospholipid Antibody Syndrome (CAPS) is a rare condition in which life-threatening blood clots form in multiple organs simultaneously and can lead to multi-organ system failure and death.
- Trial name
- NCT01029587
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Johns Hopkins University
Kidney Diseases, End Stage Renal Disease
Ixazomib for Desensitization
The purpose of this research study is to find out how well ixazomib (the study drug) works to desensitize highly sensitized kidney transplant recipients.
- Trial name
- IXADES (NCT03213158)
- Testing
- Ixazomib Oral Capsule
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplant
Pilot Social Support Counseling Intervention for Kidney Transplant Candidates
Feasibility pilot social support counseling intervention for kidney transplant candidates
- Trial name
- NCT04363515
- Testing
- Social support network counseling intervention
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Allyson Hart
Renal Function and Chronic Allograft Vasculopathy
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
A controlled, randomized, open-label, multicenter study evaluating if early initiation of everolimus and early elimination of cyclosporine in de novo heart transplant recipients can improve long-term renal function and slow down…
- Trial name
- SCHEDULE (NCT01266148)
- Testing
- Cyclosporine, Mycophenolate mofetil, Corticosteroids
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant; Complications, Pain, Postoperative
Postoperative Pain Control Following Renal Transplant
This study aims to compare the effectiveness of a regional anesthetic block vs systemic intravenous (IV) lidocaine in controlling post-operative pain in kidney transplantation patients.
- Trial name
- NCT05044429
- Testing
- Intravenous Lidocaine, Transversus abdominis plane (TAP) block, Quadratus Lumborum (QL) Block
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- George Washington University
Kidney Transplant Rejection, Gastrointestinal Disorder, Functional
Conversion From MPA to Zortress (Everolimus) for GI Toxicity Post-renal Transplantation
Patients who receive renal transplantation at Barnes Jewish Hospital (BJH) are placed on triple maintenance immunosuppression, which means that patients take 3 types of immunosuppression drugs to suppress their immune system…
- Trial name
- NCT02974686
- Testing
- Everolimus, Mycophenolic Acid
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Washington University School of Medicine